Myomo, Inc. (MYO) Stock Price & Analysis
Myomo, Inc. (MYO) fell 3.00% to USD 0.97 as of July 25, 2026 at 09:16 UTC, according to Nexqual real-time market data.
MYO last closed at USD 1; the session ranged USD 0.96–1.06 on volume of 260,252 shares. Market capitalization is $37.48M, with a 52-week range of USD 0.61–2.2 (ASE). Source: Nexqual, July 25, 2026 at 09:16 UTC.
Key Statistics (as of July 25, 2026 at 09:16 UTC)
| Price | USD 0.97 |
|---|---|
| Change | ▼ 3.00% (down) |
| Previous Close | USD 1 |
| Open | USD 1.04 |
| Day Range | USD 0.96 – 1.06 |
| 52-Week Range | USD 0.61 – 2.2 |
| Volume | 260,252 shares |
| Market Cap | $37.48M |
| Exchange | ASE |
Technical Analysis (MYO)
Nexqual's technical model rates MYO "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:16 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.39 (neutral) |
| vs SMA50 | Below (USD 1.11) |
| MACD | -0.04 (negative) |
Analyst Ratings (MYO)
Wall Street analysts rate MYO "None" based on 5 analysts, with a mean price target of USD 4.42 (range USD 1.1–10), per Nexqual as of July 25, 2026 at 09:16 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 4.42 |
| High Target | USD 10 |
| Low Target | USD 1.1 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (MYO)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.1 |
| Revenue Estimate | $10.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.09 vs est -0.12 ▲ beat |
| 2025-12-31 | USD -0.09 vs est -0.09 ▼ miss |
| 2025-09-30 | USD -0.09 vs est -0.11 ▲ beat |
| 2025-06-30 | USD -0.11 vs est -0.11 ▼ miss |
Source: Nexqual, July 25, 2026 at 09:16 UTC.
Financials & Fundamentals (MYO)
| Total Revenue | $41.21M |
|---|---|
| Revenue Growth (YoY) | +2.90% |
| Gross Margin | +65.96% |
| Operating Margin | -31.22% |
| Profit Margin | -36.69% |
| ROE | -98.53% |
| Debt / Equity | 210.65 |
| Current Ratio | 2.73 |
| Total Cash | $15.70M |
| Total Debt | $18.96M |
| Free Cash Flow | $-10.47M |
Source: Nexqual, July 25, 2026 at 09:16 UTC.
Financial Health Score (MYO)
Nexqual rates Myomo, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 09:16 UTC.
| Growth | Strong — Revenue +26% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Weak — $16M cash vs $19M debt |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Critical — ROE -99%, ROA -22.6% |
Ownership (MYO)
| Insider Ownership | +9.10% |
|---|---|
| Institutional Ownership | +40.58% |
| Shares Outstanding | 38.64M |
| Float | 26.84M |
| Short % of Float | +7.10% |
Source: Nexqual, July 25, 2026 at 09:16 UTC.
Leadership (MYO)
Myomo, Inc. is led by Paul R. Gudonis (age 70), President, CEO & Chairman, per Nexqual as of July 25, 2026 at 09:16 UTC.
| President, CEO & Chairman | Paul R. Gudonis (age 70) |
|---|---|
| Chief Financial Officer | David A. Henry (age 64) |
| Global Director of Operations | Colin Anderson |
| Senior Director of Human Resources | Galina Shtivelman |
| Sr. Director of Clinical Outcomes | Kathy Sawyers |
Major Backers & Investors (MYO)
Notable institutional backers of Myomo, Inc. include Rosalind Advisors, Inc., Jefferies Financial Group Inc., Fidelity, according to Nexqual as of July 25, 2026 at 09:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rosalind Advisors, Inc. | 9.96% |
| Jefferies Financial Group Inc. | 1.82% |
| Fidelity | 1.49% |
| Clearstead Advisors, LLC | 1.1% |
| AQR Capital Management, LLC | 0.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.2% |
| Vanguard Group | 6.37% |
| Geode Capital | 2.22% |
| State Street | 0.99% |
| Nuveen | 0.96% |
Source: Nexqual, July 25, 2026 at 09:16 UTC.
From Myomo, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- During this fitting, the device will be calibrated to the user's individual muscle signal profile using our proprietary software, and adjustments to the brace can be made to optimize fit. • The patient is provided with initial training and a set of take-home tasks to practice with the brace donned.
Partnerships
- In some cases, patients undergo amputation and receive myoelectric prosthetics rather than deal with a paralyzed arm.   Spinal Cord Injuries   According to the Christopher and Dana Reeve Foundation, spinal cord injuries are second only to strokes as a cause of paralysis, resulting in 27% of cases of paralysis.
- We have entered into agreement with O&P providers in the United Kingdom, Denmark, Germany, Italy, and Australia.   Competition   An individual with difficulty walking has a wide range of technological alternatives from canes and crutches to powered wheelchairs and exoskeleton suits.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MYSZ | My Size, Inc. | USD 0.42 | ▲ 0% |
| MBOT | Microbot Medical Inc. | USD 1.71 | ▼ 3.39% |
| LMFA | LM Funding America, Inc. | USD 2.6 | ▲ 18.18% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
| TENX | Tenax Therapeutics, Inc. | USD 14.53 | ▼ 1.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:16 UTC. This page is informational and not investment advice.